Literature DB >> 15941836

Is DAS28 an appropriate tool to assess remission in rheumatoid arthritis?

H Mäkinen1, H Kautiainen, P Hannonen, T Sokka.   

Abstract

OBJECTIVES: To study which cut off point of DAS28 corresponds to fulfilment of the American Rheumatism Association (ARA) preliminary remission criteria, and clinical remission criteria in patients with rheumatoid arthritis (RA).
METHODS: All adult patients diagnosed with RA at Jyväskylä Central Hospital 1997-98 were assessed for remission at 5 years. Remission was defined as (a) ARA remission; (b) clinical remission (defined as no tender or swollen joints and normal erythrocyte sedimentation rate). DAS28 was used to measure disease activity. A receiver operating characteristics curve analysis was performed to calculate a cut off point of DAS28 that best corresponds to the ARA remission criteria and the clinical remission criteria.
RESULTS: 161 patients (mean age 57 years, 107 (66%) female, 98 (61%) with positive rheumatoid factor, and 51 (32%) with erosions) were studied. At 5 years, 19 (12%) patients met the ARA remission criteria, and 55 (34%) met the clinical remission criteria. The cut off value of DAS28 was 2.32 for the ARA remission criteria, and 2.68 for the clinical remission criteria. In patients with DAS28 <2.32, 11/57 (19%) had tender joints, 6/57 (11%) had swollen joints, and 4/57 (7%) had both tender and swollen joints (66 joint count).
CONCLUSION: In this study the DAS28 cut off point for the ARA remission was lower than in previous studies. The cut off point for DAS28 remission remains controversial. A substantial proportion of patients below the DAS28 cut off point for remission have tender or swollen joints, or both. DAS28 may not be an appropriate tool for assessment of remission in RA.

Entities:  

Mesh:

Year:  2005        PMID: 15941836      PMCID: PMC1755218          DOI: 10.1136/ard.2005.037333

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  23 in total

Review 1.  Clinical outcome measures in rheumatoid arthritis.

Authors:  P L van Riel; A M van Gestel
Journal:  Ann Rheum Dis       Date:  2000-11       Impact factor: 19.103

2.  Remission and response to early treatment of RA assessed by the Disease Activity Score. BARFOT study group. Better Anti-rheumatic Farmacotherapy.

Authors:  B Svensson; C Schaufelberger; A Teleman; J Theander
Journal:  Rheumatology (Oxford)       Date:  2000-09       Impact factor: 7.580

3.  Value of Disease Activity Score 28 (DAS28) and DAS28-3 compared to American College of Rheumatology-defined remission in rheumatoid arthritis.

Authors:  Alejandro Balsa; Loreto Carmona; Isidoro González-Alvaro; Miguel Angel Belmonte; Xavier Tena; Raimon Sanmartí
Journal:  J Rheumatol       Date:  2004-01       Impact factor: 4.666

Review 4.  Defining remission in rheumatoid arthritis: what is it? Does it matter?

Authors:  Howard E Paulus
Journal:  J Rheumatol       Date:  2004-01       Impact factor: 4.666

5.  The original "DAS" and the "DAS28" are not interchangeable: comment on the articles by Prevoo et al.

Authors:  D M van der Heijde; J W Jacobs
Journal:  Arthritis Rheum       Date:  1998-05

6.  Radiographic remission in seropositive rheumatoid arthritis. A 20-year follow-up study.

Authors:  J Jäntti; K Kaarela; H Kautiainen; H Isomäki; K Aho
Journal:  Clin Exp Rheumatol       Date:  2001 Sep-Oct       Impact factor: 4.473

Review 7.  Early inflammatory polyarthritis: results from the Norfolk Arthritis Register with a review of the literature. II. Outcome at three years.

Authors:  B Harrison; D Symmons
Journal:  Rheumatology (Oxford)       Date:  2000-09       Impact factor: 7.580

8.  Treatment of early RA in clinical practice: a comparative study of two different DMARD/corticosteroid options.

Authors:  B Svensson; M Ahlmén; K Forslind
Journal:  Clin Exp Rheumatol       Date:  2003 May-Jun       Impact factor: 4.473

9.  Most patients receiving routine care for rheumatoid arthritis in 2001 did not meet inclusion criteria for most recent clinical trials or american college of rheumatology criteria for remission.

Authors:  Tuulikki Sokka; Theodore Pincus
Journal:  J Rheumatol       Date:  2003-06       Impact factor: 4.666

10.  Prognostic factors in a large cohort of patients with early undifferentiated inflammatory arthritis after application of a structured management protocol.

Authors:  Mark A Quinn; Michael J Green; Helena Marzo-Ortega; Susanna Proudman; Zunaid Karim; Richard J Wakefield; Philip G Conaghan; Paul Emery
Journal:  Arthritis Rheum       Date:  2003-11
View more
  51 in total

1.  Rheumatoid arthritis: 2011 remission criteria are a new benchmark for RA therapy.

Authors:  Vivian P Bykerk
Journal:  Nat Rev Rheumatol       Date:  2011-05-10       Impact factor: 20.543

Review 2.  Remission in juvenile idiopathic arthritis: current facts.

Authors:  Susan Shenoi; Carol A Wallace
Journal:  Curr Rheumatol Rep       Date:  2010-04       Impact factor: 4.592

3.  Residual disease activity in rheumatoid arthritis patients treated with subcutaneous biologic drugs that achieved remission or low disease activity: a longitudinal observational study.

Authors:  Fabio Massimo Perrotta; Antonia De Socio; Silvia Scriffignano; Ennio Lubrano
Journal:  Clin Rheumatol       Date:  2018-02-21       Impact factor: 2.980

4.  Revising DAS28 scores for remission in rheumatoid arthritis.

Authors:  Claire Sheehy; Verity Evans; Heather Hasthorpe; Chetan Mukhtyar
Journal:  Clin Rheumatol       Date:  2014-01-03       Impact factor: 2.980

5.  Predictors and persistence of new-onset clinical remission in rheumatoid arthritis patients.

Authors:  Iris Navarro-Millán; Lang Chen; Jeffrey D Greenberg; Dimitrios A Pappas; Jeffrey R Curtis
Journal:  Semin Arthritis Rheum       Date:  2013-06-03       Impact factor: 5.532

Review 6.  Defining remission in rheumatoid arthritis: results of an initial American College of Rheumatology/European League Against Rheumatism consensus conference.

Authors:  Lilian H D van Tuyl; Steven C Vlad; David T Felson; George Wells; Maarten Boers
Journal:  Arthritis Rheum       Date:  2009-05-15

7.  Foot function in rheumatoid arthritis patients: a cross-sectional study.

Authors:  Agnes Patricia de Andrade; Elinah Narumi Inoue; Renato Nisihara; Thelma Larocca Skare
Journal:  Clin Rheumatol       Date:  2018-07-14       Impact factor: 2.980

8.  Cartilage oligomeric matrix protein (COMP) in rheumatoid arthritis and its correlation with sonographic knee cartilage thickness and disease activity.

Authors:  Rajalingham Sakthiswary; Shamala Rajalingam; Heselynn Hussein; Radhika Sridharan; Abdul Wahab Asrul
Journal:  Clin Rheumatol       Date:  2017-09-09       Impact factor: 2.980

9.  Determining a low disease activity threshold for decision to maintain disease-modifying antirheumatic drug treatment unchanged in rheumatoid arthritis patients.

Authors:  Michel de Bandt; Bruno Fautrel; Jean Francis Maillefert; Jean Marie Berthelot; Bernard Combe; René-Marc Flipo; Frédéric Lioté; Olivier Meyer; Alain Saraux; Daniel Wendling; Xavier Le Loët; Francis Guillemin
Journal:  Arthritis Res Ther       Date:  2009-10-23       Impact factor: 5.156

10.  Forefoot disease activity in rheumatoid arthritis patients in remission: results of a cohort study.

Authors:  Marike van der Leeden; Martijn Pm Steultjens; Dirkjan van Schaardenburg; Joost Dekker
Journal:  Arthritis Res Ther       Date:  2010-01-07       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.